Addition of exogenous galectin-3 significantly improved net efferocytosis (39.6 (±17.8)%) compared with untreated MDMs (baseline: 33.2 (±17.7)%; p = 0.002) in the cohort with asthma (Fig. 2a). Here, LGALS3 is linked to asthma.